More specifically, the analysis revealed that the mRNA-based subtype of the Lebanese samples is luminal B as SFRP1, KRT14, KRT5, EGFR, CDH3, MYC and FOXC1 were downregulated, while MLPH, MAPT, ESR1, SLC39A6, CEP55, UBE2C, CDC6, PTTG1, CDC20 and BIRC5 were upregulated in accordance to the differential expression of 50 genes used in the Prosigna breast cancer gene signature assay (PAM50)8. The gene discussed is MLPH; the disease is breast cancer.